It has long been known that injured axons in the brain and spinal cord of adult mammals do not regenerate. It has been known almost as long, that the lack of such axon regeneration is not due to an intrinsic inability of adult mammalian CNS neurons to regenerate axons, but rather to the non-permissiveness of the immediate surroundings of the injured axons. After axotomy in the CNS very local sprouting, termed "abortive sprouting" by Ramón y Cajal, can be seen to emerge from both ends of a cut axon, (see Ramón y Cajal, 1928; Olson, 1997) , but such sprouts do not elongate in white matter. For an exposé of the early days and the proponents of negative neurotropism, not the least the work of Lugaro, and the fact that CNS axons can, but are typically inhibited from regeneration, see Fraidakis, (2010). A compelling demonstration of regeneration of adult mammalian CNS axons exposed to the environment of peripheral nerve tissue was provided by Tello, who showed that axon bundles invaded grafts of pieces of peripheral nerves placed in the cerebral cortex of rabbits, and that axon growth into the grafts was better and followed the bands of Büngner, if the nerve grafts had been predegenerated (Tello, 1911) . The source of the "neurotropic substances" was thought to be Schwann cells (Marinesco, 1906) . Implantation of peripheral nerve grafts into the CNS was repeated in the 40s (Le Gros Clark, 1943) and the possible use of peripheral nerve grafts as bridging conduits for regenerating CNS axons was demonstrated by Aguayo and collaborators (Richardson et al., 1980) . Later, multiple bridges of peripheral nerves across a complete transection of the spinal cord were shown to allow a degree of functional recovery in adult rats
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Inhibitors of axon regeneration
Ernesto Lugaro was a prominent neuroscientist of his time, supporting the Neuron Doctrine as proposed by Waldeyer (1891) and Cajal's Neurotropism hypothesis. He found the cerebellar Experimental Neurology 248 (2013) [309] [310] [311] [312] [313] [314] [315] E-mail address: lars.olson@ki.se.
"Lugaro cells", coined the term "plasticity" and hypothesized a chemical nature of neurotransmission (see Fraidakis, 2010) . Arguably, Lugaro was also the first to suggest that CNS white matter actively inhibits axon regeneration. His "Negative neurotropism" hypothesis was based on his findings that motor axons could regenerate in the dorsal root but only as far as the dorsal root entry zone, where they were instead repulsed and took other routes, such as in the pia mater. Martin Berry obtained early experimental support for the inhibitory effect of CNS myelin (Berry, 1982) . The the pioneering work of Martin Schwab and his collaborators (Caroni and Schwab, 1988a; Caroni and Schwab, 1988b , see also Schwab, 2010; Petersen et al., 2012a Petersen et al., , 2012b Karlsson et al., 2013) finally led to the identification of an inhibitory component of myelin and the cloning of the Nogo gene (Chen et al., 2000; Prinjha et al., 2000; GrandPre et al., 2000) , which was followed by cloning of the first Nogo receptor (Fournier et al., 2001 ). There has been a formidable recent development of this field, with the discovery of the additional inhibitors in myelin, MAG (McKerracher et al., 1994; Mukhopadhyay et al., 1994) and OMgp (Wang et al., 2002b) , the Nogo receptors NgR2 and NgR3 (Laurén et al., 2003 (Laurén et al., , 2007 , and additional receptors, coreceptors and interacting proteins, including p75 (Wang et al., 2002a) , Lingo (Mi et al., 2004) , Troy (Park et al., 2005; Shao et al., 2005) , PirB (Syken et al., 2006; Atwal et al., 2008) , and Lotus (Sato et al., 2011) , and additional components of the complex signaling systems that regulate growth and plasticity in the central nervous system (Borrie et al., 2012; Dickendesher et al., 2012; Schwab, 2010) .
Shifting focus from white to gray matter
Having identified Nogo as a key inhibitory protein of CNS myelin, there was a focus on Nogo's role in white matter and the possibilities that Nogo inhibition might offer to stimulate long distance axon regeneration. It was then found that Nogo is expressed not only by oligodendrocytes, but by many neurons as well (Josephson et al., 2001b) , and that NgR1 was exclusively expressed by neurons (Fournier et al., 2001; Josephson et al., 2002) . Moreover, NgR mRNA expression is promptly down-regulated by increased neuronal activity (Josephson et al., 2003) . It was thus hypothesized that temporary NgR1 down-regulation could be important for synaptic plasticity underlying the formation of lasting memories and the idea obtained support in a transgenic mouse with inducible activity-insensitive expression of a NgR1 transgene in forebrain neurons (Karlén et al., 2009) . Importantly, mice lacking NgR1 were found to maintain ocular dominance shift plasticity into adulthood (McGee et al., 2005) . While these findings and similar observations in Nogo A knockout mice were interpreted as due to a role for the Nogo A present in myelin, the expression of Nogo in neurons (Josephson et al., 2001b) suggests that the increased plasticity in adult mice lacking either NgR1 or Nogo A is caused by increased plasticity at the synaptic level in gray matter (see Akbik et al., 2012; Pernet and Schwab, 2012) .
The fact that interfering with Nogo-NgR signaling is likely to have effects not only in white, but also in gray matter has helped interpretation of animal models of incomplete spinal cord injury. Thus rather than long distance regeneration of axons in white matter, which is hindered not only by the presence of Nogo, but also at the site of injury by several components of local scarring, sprouting from remaining axon systems, distant from the lesion site, and even onto other non-injured neurons, able to relay signals within the spinal cord, has been demonstrated to occur and have functional effects (see Petersen et al., 2012a Petersen et al., , 2012b . Moreover, plastic changes in response to spinal cord injury also occur in the brain, in a manner that involves local down-regulation of NgR1 (Endo et al., 2007) .
The complex pathology of spinal cord injury
The normal nerve growth forbidding CNS environment described above is the context in which trauma to the CNS should be understood. After trauma to the spinal cord, the damaged tissue undergoes a series of pathological and reactive alterations, most of which serve to contain the damage, avoid infection, and take care of debris, rather than to actively support recovery. A plethora of cells, including activated astrocytes, activated microglia, proliferating pericytes, macrophages and other cells of the immune system enter the damaged area and its surroundings. A breach in the blood-spinal cord barrier causes leakage of proteins and other blood components (see Abrams et al., 2012) , dead and damaged cells will be present, edemas will form and can lead to cysts (Josephson et al., 2001a) , and excess chondroitin sulphate proteoglycans (CSPGs) become deposited in the extracellular space (Morgenstern et al., 2002; Sharma et al., 2012) . Digestion of CSPGs has proven an effective means to enhance nerve fiber growth and sprouting after injury (Bradbury et al., 2002; Starkey et al., 2012) . This supports previous observations that microtransplants of adult sensory neurons, small enough not to evoke a CSPG scar formation, are able to regenerate long axons in intact as well as actively degenerating spinal cord white matter (Davies et al., 1999) , even though such neurons may express NgR1 (Josephson et al., 2001a (Josephson et al., , 2001b .
Ischemia and other adverse circumstances at the site of injury may also lead to the death of oligodendrocytes needed to support nondisrupted axons in the traumatized area. Such spared sets of locally demyelinated axons, supported by their distant cell bodies, constitute an important target for treatment aimed at improving their conduction properties and their long term survival by the provision of new myelin sheaths.
Importantly, a localized spinal cord injury will also lead to distant effects. Degeneration of ascending and descending axons, interrupted at the injury site, will cause white matter pathology at many levels. Masses of myelin sheaths will have to be phagocytized. For instance, reactive astrocytes with increased GFAP immunoreactivity will be found along almost the entire length of the injured rat spinal cord for a long period of time (Widenfalk et al., 2001) .
A thoracic injury will cause silencing of sensory inputs to the brain from the hind limbs. This will elicit compensatory changes of cortical circuitry, including decreased NgR expression, and increased BDNF expression in the corresponding and neighboring cortical areas, presumably to allow plastic changes, prioritizing forelimb inputs (Endo et al., 2007) . Such plasticity, while useful if the spinal cord remains severed, may become a hindrance to the reestablishment of a normal cortical input if the spinal cord is later repaired. Severe injury will also cause deterioration of health, including muscle wasting, and there will be the risk of decubitus ulcers and urinary infections.
Treatment strategies
There are no drugs with robust effects available for clinical use in spinal cord injury. However, there are several finished and ongoing clinical trials of different drugs for neuroprotection or to stimulate regeneration, as well as trials of cell engraftment procedures (Sahni and Kessler, 2010; Gensel et al., 2011; Fehlings et al., 2011; Casha et al., 2012; Tabakow et al., 2013) . Ongoing trials include delivery of Nogo antibodies (Filli and Schwab, 2012) . Other trials will hopefully start soon. Thus oral monotreatment with Imatinib (Glivec) leads to improved recovery from spinal cord injury in rats (Abrams et al., 2012) . The fact that imatinib is in routine clinical use for other indications (cancer), should shorten the road to clinical trials of this particular drug in spinal cord injury.
How should one go about attempting to minimize the effects of spinal cord injury? Very soon after incomplete injury, treatments may help protect damaged spinal tissue, including its most important elements, the white matter axon bundles, from secondary injury occurring in the first few weeks after the primary injury. While such protection will not restore any communication across injury if the cranial and caudal parts of the spinal cord are completely separated, a neuroprotective regimen could still be beneficial, perhaps rescuing certain functions at the distal end of the cranial stump and setting the stage for other future treatments aimed to bridge the communication gap.
Interruption of ascending and descending axon pathways will cause permanent functional impairments. In addition to the attempts to rescue as many axons as possible, there are therefore also several approaches aiming at stimulating regeneration of cut axons and provide them with biological or artificial bridging scaffolds. Recently, efforts have also been made to bypass injury by electronic devices and interfaces. Finally, there are treatments that encourage compensatory terminal sprouting and other structural rearrangements at different levels of the neuraxis.
Evolution is unlikely to have developed a system to actively inhibit long distance axon regeneration in the adult mammalian central nervous system. Other roles for the Nogo system in white matter therefore need to be worked out, such as the arrangement of the oligodendrocytederived myelin sheath (Chong et al., 2012) . Nevertheless, the inhibitors are so powerful, that they are difficult to overcome by mere delivery of known nerve growth stimulatory factors. Inhibition of Nogo signaling has proven helpful in different models of CNS injury, such as spinal cord injury (see Liebscher et al., 2005; Cafferty et al., 2010) and stroke (see Tsai et al., 2011 and references therein) . Experimentally, Nogo signaling can be blocked at different levels, using gene deletion strategies, blocking Nogo antibodies, NgR antibodies or a soluble NgR decoy strategy. Alternatively, as the intracellular pathways become known, downstream (see Kopp et al., 2012) and possibly upstream intervention strategies could be developed.
Treatment with one drug does not reveal its full potential
The majority of experimental SCI treatment studies investigate the effect of a single treatment. In the often used weight drop injury model, several different drugs show effects of a similar magnitude, almost as if there was a ceiling effect, perhaps due to rescue of remaining demyelinated but initially non-interrupted axons, which can presumably be achieved in a number of different ways. If this were the cause of the seemingly similar, relatively modest positive effects of a number of different drugs, it would not help to combine such drugs. Instead, to obtain additive or synergistic effects one needs to combine treatments targeting different mechanisms. However, as soon as treatments/drugs are combined, matters get complicated.
A single treatment/drug can have a net effect that ranges from negative, via no detectable effect to positive. In neither case will the potentially useful effects of a given treatment/drug be fully understood from a single mono-treatment study, if a combinatorial treatment is planned. When two drugs are combined, they may act independently of each other (additive effect, 1 + 1 = 2), or, if targeting the same mechanism, not have additive effects (1 + 1 = 1). Alternatively, the two drugs may lead to synergistic effects (larger than the sum of the two individual drugs, 1 + 1 = 3), or interact negatively (1 + 1 = 0). In addition, there may be situations in which neither of two drugs is effective alone, while the combination has an effect (0 + 0 = 1) or when one drug without effect on its own can become effective when combined with a second drug (0 + 1 = 2). In fact, when two drugs, each with the possibility to exert one of three effects (−1, 0, 1) are combined, and additive, positive and negative synergy effects are taken into account, the number of possible outcomes increases rapidly. It follows that combining 3 or more drugs/treatments is associated with a correspondingly larger number of possible outcomes. To simplify the challenge of combining treatments one may focus on combining treatments that, when used as single treatments, have positive effects and are unlikely to interact with each other. With regard to combining drugs/ treatments that are unlikely to exert negative effects, a reasonable approach is to begin by combining several, and then systematically removing drugs/treatments until it affects outcome negatively.
In spinal cord injury many things go awry. It is thus highly unlikely that a treatment based on a single intervention, such as one drug or one type of cell implantation, would be able to counteract all or most aspects of the damage. Accordingly, an increasing number of experimental studies have combined different treatments to obtain better recovery. Promising results of combining trophic factors and cellular elements in different ways have been reported (see reviews by Blesch et al., 2002; Kwon and Tetzlaff, 2001; Fortun et al., 2009 ). Examples of recent work include the use of GDNF-expressing Schwann cells to stimulate nerve growth and recovery (Deng et al., 2013) , delivery of BDNF and chondroitinase to enhance regeneration through peripheral nerve grafts (Tom et al., 2013) , combining acidic FGF with peripheral nerve grafts to improve gait after complete spinal cord transection (Lee et al., 2010) , or, when also adding chondroitinase, to restore bladder function (Lee et al., 2013) , combining adult neural stem/ progenitor cells with growth factors and chondroitinase to promote repair of the chronically injured spinal cord (Karimi-Abdolrezaee et al., 2010) , and the use of neurotrophin-secreting Schwann cells and Rolipram to promote recovery (Flora et al., 2012) .
Injury to the CNS differs from injury to other organs in that the specific blood-brain barrier or blood-spinal cord barrier is breached. CNS injury also differs from injury to other organs by being contained within a non-expandable bone compartment such that bleedings and edema can have catastrophic consequences. One or more components of an acute treatment should therefore be focused on dampening inflammatory and immune responses, as well as normalizing the blood-spinal cord barrier. A second goal should be to inhibit scar formation and the deposition of increased amounts of CSPG. As mentioned elsewhere in this review, enzymatic digestion of CSPGs has proven remarkably helpful as a means to remove one key obstacle to nerve fiber growth. There is recent evidence that the CSPGs not only provide a physical barrier to nerve growth, but that these extracellular proteins are also ligands to Nogo receptors NgR1 and NgR3 (Dickendesher et al., 2012) . Because there is also widespread expression of Nogo, MAG and OmGP in myelin and of Nogo in neurons, different ways to block Nogo receptor mediated nerve growth inhibition have been shown to improve nerve fiber growth. Additional approaches that can be combined with all of the above include delivery of neurotrophic factors, providing scaffolds for nerve fiber growth, either biological such as peripheral nerve grafts, or artificial, as well as delivery of many different types of cells, to provide trophic support, to help remyelinate denuded axons, to serve as a conduit for nerve growth, or, in the form of neurons, to replace or substitute for lost neuronal pathways. To these interventions should be added the value of physical training programs.
There are many examples of how different cell types used for grafting have not been grafted in their native condition, but genetically altered to improve protective or reparative properties and diminish possible negative effects (e.g. Hofstetter et al., 2005) and of a number of other combinatorial approaches. In one model three treatments with different targets were combined. The neurotrophin NT3 was delivered by transgenic NT3-secreting fibroblasts to stimulate nerve growth, a viral construct was used to deliver the NR2D subunit of the NMDA receptor to improve synaptic connectivity and injections of chondroitinase ABC were used to remove extracellular CSPG (García-Alías et al., 2011). Training has been combined with interventional therapy such as ChABC (see García-Alías and Fawcett, 2012) and is not always additive in combination with drug treatments (Maier et al., 2009 ).
Combinatorial treatment for regeneration of sensory pathways
A recent experimental study published in this journal uses optic nerve and spinal cord crush models to examine this issue. In both experiments, sensory nerve fibers regenerating towards the brain were investigated, originating from the retinal ganglion cells and dorsal root ganglion cells, respectively. In the optic nerve model, Wang and collaborators find that while lack of Nogo receptor 1 or activation of macrophages and causing a sterile inflammation using an intraocular zymosan A injection improves axon regeneration to about the same degree, the combination of the two leads to synergistic effects in terms of numbers of regenerating optic nerve axons (Fig. 1) . This supports and extends earlier findings in the same model system (Fischer et al., 2004) .
Wang et al. went on to investigate combinatorial treatments in a spinal cord dorsal column injury model, using a rather demanding combination of drug delivery strategies (Fig. 2) . They labeled ascending sensory tracts with CTB and found that three different single treatments, icv delivery of Chondroitinase ABC (ChABC), infusion of a soluble Nogo receptor decoy (NgR310-Fc) and preconditioning dorsal root ganglion cells by a sciatic nerve lesion, all stimulated regeneration of ascending CTB-labeled fibers to a degree. None of the three possible paired treatments caused better regeneration, while the combination of all three treatments caused longer axon regeneration. Remarkably, the triple treatment allowed regenerating fibers to extend through and several millimeters beyond the site of injury (Fig. 1) . Wang et al. (2012) therefore suggests that combinatorial treatments are of clinical interest, and likely to have better effects than any one single treatment. While none of the two types of treatments studied in the current optic nerve and spinal cord models could be fully used in a clinical setting, they do add to the literature suggesting that counteracting Nogo-NgR signaling can improve regeneration/sprouting in CNS tissue and that both ChABC and preconditioning peripheral lesions can improve central regeneration of sensory neurons. Wang et al. also investigated if the sciatic nerve lesion could be carried out at the time of spinal cord injury or even 3 days later. In both cases was there an effect, albeit lesser than when the nerve had been lesioned a week before the spinal cord.
Overall, it appears that ChABC treatment is an important constituent, not only by allowing regenerating fibers to cross the injury site, but also by leading to a markedly increased number of labeled fibers just caudal of the injury site. The key role of digesting CSPGs (chondroitin sulphate proteoglycans) in injury models is in line with the striking observations by Silver and coworkers that neurons that are micrografted into adult intact, or even degenerating white matter using a fine glass pipette are able to extend axons for long distances in the white matter, presumably because the grafting technique does not elicit any activation of CSPG deposition around the grafted neurons (Davies et al., 1997 (Davies et al., ,1999 . The findings of Davies et al. provides support for the idea that the primary role for Nogo in white matter tracts may not be to inhibit nerve growth, although this may be important, e.g. at the nodes of Ranvier, in order to inhibit axon branching. Much of the difficulties with regeneration in white matter may instead be due to the accumulation of CSPG material at sites of injury. The microstereology of intact white matter may be such that certain axons can indeed grow for long distances (Fig. 2) .
The two regeneration experiments have one treatment in common, ways to protect the regenerating axons from being inhibited by Nogo. The optic nerve study accomplished this by the use of NgR1 knockout mice. The spinal cord study was conducted in rats, and Nogo was instead neutralized by delivery of a soluble NgR1 decoy, as pioneered by the authors (Fournier et al., 2002) . A difference between these two approaches is that in the optic nerve experiment, Nogo will still be able to bind to other receptors, such as NgR2, NgR3, PirB and other as yet not defined receptors, while in the spinal cord experiment, all effects of Nogo are more or less inhibited, while instead possible effects of other ligands, such as MAG and OMgp may remain.
As for activation of ganglion cells in the two model systems, the authors used Zymosan for the retinal cells, and lesioning of the peripheral axon for the dorsal root neurons. These two modes of activation may possibly have some features in common, and while axotomy is not an option in a clinical trial, activation by Zymosan or other compounds could perhaps be used.
Wang et al. have demonstrated that several different single treatments and, particularly, combinations of treatments can stimulate regeneration of sensory fibers in the injured optic nerve and spinal cord. A next step would be to demonstrate that such regeneration can continue until it reaches relevant brain areas or until signals from regenerating fibers can be relayed by intact pathways on the central side of the lesions, and thus lead to functional improvements. For observations of such effects in the spinal cord model, electrophysiological studies would be needed or the sciatic nerve would have to regenerate, as it may after constriction injury, when sparing the perineurium around individual bundles (see Olson, 1969) .
Importance of repairing descending and ascending tracts
There is strong evidence that the corticospinal tract (CST) is of crucial importance for most aspects of walking in humans, the only fully bipedal primate species (Nielsen, 2002 , 2003 , Petersen et al., 2012a , 2012b , Castermans and Duvinage, 2013 Jain et al., 2013; Hiraoka and Abe, 2007; Madhavan et al., 2011; Petersen et al., 2003 Petersen et al., , 2012a Sahyoun et al., 2004; Barthélemy et al., 2012) . This is a good reason to maintain focus on the rescue and repair of the corticospinal tract (CST) also in rodent work, even if the relative role of the CST might be lesser in these species. One should note, however, that while rats, unlike humans, with complete transection of the spinal cord can be made to generate alternating walking-like movements with their hindlimbs when given an appropriate sensory input (such as a moving treadmill) and/or monoaminergic drugs, such findings do not prove that this is how walking is carried out in intact animals. There are other examples, such as heart rate control, where successively lower layers of functional control are being activated when higher levels of control fail. There are in fact indications that the corticospinal tract is of importance not only for the forelimbs, but also for the hindlimbs, also in rats (Tsai et al., 2005) . It should also be noted that rats that have had the spinal cord lesioned at a thoracic level, will remain permanently paralyzed, as will human beings.
As important as the CST may be for human walking, recovery of function of the ascending sensory systems is equally important. It is therefore gratifying to see that a degree of regeneration of these systems has been accomplished by the two types of triple treatments introduced by Wang et al. (2012) .
Neural stem cells accompanied by a 10-factor cocktail
Recently, another group published work in which they used a cocktail of no less than 10 factors (NT-3, BDNF, EGF, βFGF, GDNF, PDGF, αFGF, HGF, IGF-1 and calpain inhibitor) in a fibrin gel to support rat or human neural stem cells grafted to the completely transected spinal cord of adult rats (Fig. 3) . Wang et al. (2012) . A preconditioning crush of the sciatic nerve on one side is carried out a week before the spinal cord injury. ChABC, which is unstable at body temperature, is delivered into a cerebral ventricle every second day after injury via a stereotaxically fixed cannula. The Nogo receptor decoy NgR(310)-Fc is delivered to the subdural space at the site of injury using an osmotic minipump. The CTB label is delivered to this injured sciatic nerve, proximal to the crush. (From Wang et al., 2012 , with permission). Wang et al. (2012) . In the optic nerve experiment, numbers of regenerated fibers at different distances from the lesion are shown for control mice (wt), NgR1−/− mice, as well as for these two genotypes given zymosan (zym) into the posterior parts of the eye. In the spinal cord study, control IgG is compared to preconditioning by a sciatic nerve lesion (PCI), delivery of a NgR decoy (NgR), delivery of chodroitinase ABC (ChABC), the three possible pairwise combinations of these three singe treatments, as well as the combination of all three treatments. Figure composed Complete T3 transection of the spinal cord was carried out in rats with removal of a 2 mm segment of the cord. The researchers then dissociated cells from E14 spinal cord tissue from transgenic rats ubiquitously expressing GFP. Such cell suspensions were mixed into a fibrin matrix containing the ten factors and the cell rich fibrin mixture was injected into the lesion cavities 2 weeks after spinal cord injury. While the trophic cocktail probably exerted most of its effects on the cells in the fibrin matrix, it is known that implanted fibrin glue loaded with a trophic factor (GDNF) can provide slow release of such a protein for about a week (Cheng et al., 1998) .
Two kinds of human neural stem cells were also grafted to rodents using a similar approach. Grafted rodent cells and their processes were detected by the presence of GFP and large numbers of a variety of GFP-positive neurons and other cell types were found. The grafted neurons extended remarkably large numbers of neurites both cranially and caudally into the cut ends of the host spinal cord and made synaptic contacts with host spinal cord neurons. The grafted cells and their processes were shown to carry electrical signals across the injury site leading to functional recovery that disappeared upon retransection of the host spinal cord (Fig. 4) .
It is known that the spinal cord distal to an injury that completely separates it from contacts with the cranial stump is maintained in reasonably good condition for decades of post-injury life in humans (Bunge et al., 1993) . Thus repair of the spinal cord by bridging techniques that show effects in the completely severed spinal cord soon after injury (Cheng et al., 1996; Lu et al., 2012) might also be applied to patients with chronic spinal cord injury. In such cases, removal of scar tissue on the spinal cord surfaces opposing the bridge implant would almost certainly be needed. In rats, the multiple peripheral nerve bridge technique, which uses fibrin glue containing aFGF, has also been applied to animals with chronic complete spinal cord injury. By removal of scar tissue to expose fresh spinal cord tissue at the surfaces of the spinal cord stumps, such bridges can restore a degree of hind limb function (Fraidakis et al., 2004) .
Concluding remarks
We have come a long way since the days of Cajal and his contemporaries. There are now a number of different approaches to improve recovery from partial as well as complete loss of continuity across a spinal cord injury in rodent models. The complexity of the task has lead to an increasing use of combinatory treatments, as exemplified by the studies by Wang et al. (2012) and Lu et al. (2012) discussed here. There is cross-fertilization between research on traumatic brain injury and spinal cord injury, which helps the development of novel strategies and serves to validate results. Positive findings may find use in both areas, as well as in a number of other conditions in the central nervous system. Indeed, there are accidents that cause a combination of traumatic brain injury and spinal cord injury in the same individuals.
In the early 70s, studies of regeneration in the adult mammalian spinal cord were rare, an example being the regeneration of descending noradrenaline and serotonin axons following mechanical or neurotoxin lesions (Nygren et al., 1971) . During the last 15 years, we have witnessed the recruitment of many laboratories, taking advantage of new basic knowledge about trophic factors, nerve growth inhibitory factors, cell and tissue transplantation procedures, the molecular biology of neurons, glial cells, and stem cells, as well as transgenic animal models and a plethora of biomedical and biotechnical achievements to diversify and accelerate progress.
Several of the effective measures taken to treat the injured spinal cord in animals cannot easily be translated into clinical trial protocols. However, a number of clinical trials have been carried out, others are ongoing, based on results from animal studies. Inspired and challenged by the basic, translational and clinical results to date, there is good reason to assume that the trend of an increasing number of researchers ready to tackle the "hard problem" -can the cut spinal cord be repaired? -will continue. The road to the establishment of clinically useful procedures may still be long, but the patience of those working toward this goal is encouraging. Fig. 4 . BBB scores of hind limb function in grafted and control rats during 7 weeks postgrafting. When the spinal cord was retransected at the interface between the cranial host spinal cord and the grafted cells, the functional improvement was lost. Fig. 6G from , with permission.
